Shares fell sharply by 16.5% as investors reacted negatively to the unexpected deceleration in type 2 diabetes customer retention and the need for increased investment in customer support, signaling concerns about the sustainability of growth in this key segment.
- Total company revenue grew 23% year-over-year on a constant currency basis, driven by strong demand and favorable price mix.
- Adjusted operating margin improved by 140 basis points, reflecting better manufacturing productivity and scale benefits.
- Adjusted EPS increased approximately 42%, supported by revenue growth and cost discipline.
- New global customer starts reached the second highest quarter ever, with strong U.S. MDI user conversions and international expansion in Spain.
- Retention and utilization among type 2 diabetes customers weakened more than anticipated, prompting a strategic shift to expand customer care, modify sales incentives, and refine sampling programs to address lower engagement and retention risks.
Community Discussion